Personalized genotyping!based therapy
https://doi.org/10.18093/0869-0189-2014-0-4-5-12
Abstract
In the postgenome era, clinical medicine is characterized by development of personalized genotypingbased approach to treatment. Clinical stud ies published in 2013–2014 and approved by FDA (Food and Drug Administration, USA) have been analyzed in this review. These include 8 clini cal studies on hematology / oncology, 3 clinical studies on endocrinology, 2 clinical studies on gastroenterology, infection diseases, respiratory dis eases, cardiology, gynecology / obstetrics, neurology and novel diagnostic procedures each and one clinical study on psychiatrics. The analysis demonstrated further development of evidencebased medicine that provided personalized genotypingbased therapy.
About the Author
A. G. Chuchalin
Pulmonology Research Institute, Federal Medical and Biological Agency of Russia
Russian Federation
Russian Federation
References
1. Wang M.L., Rule S., Martin P. et al. Targeting BTK with ibrutinib in relapsed or refractory mantlecell lymphoma. N. Engl. J. Med. 2013; 369 (6): 507–516.
2. Goede V., Fisher K., Busch R. et al. Obinutuzumab plus chlo rambucil in patients with CLL and coexisting conditions. N. Engl. J. Med. 2014; 370 (12): 1101–1110.
3. Sequist L.V., Chih'Hsin Yang J., O' Byrne K. et al. Phase 111 study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR muta tions. J. Clin. Oncol. 2013; 31 (27): 3327–3334.
4. Flaherty K.T., Infante J.R., Daud A. et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 muta tion. N. Engl. J. Med. 2012; 367 (18): 1694–1703.
5. Flaherty K.T., Robert C., Hersey P. et al. Improved survival with MEK inhibition in BRAFmutated melanoma. N. Engl. J. Med. 2012; 367 (2): 107–114.
6. Verrna S., Miles D., Gianni L. et al. Trastuzumab emtansine for HER2positive advanced breast cancer. N. Engl. J. Med. 2012; 367 (19): 1783–1791.
7. Wallace A.M., Han L.K., Povoski S.P. et al. Comparative evaluation of [(99m)tc]tilmanocept for sentinel lymph node mapping in breast cancer patients: results of two phase 3 tri als. Ann. Surg. Oncol. 2013; 20 (8): 2590–2599.
8. Parker C., Nilsson S., Heinrich D. et al. Alpha emmiter radi um223 and survival in metastatic prostate cancer. N. Engl. J. Med. 2013; 369 (3): 213–223.
9. ClinicalTrials.gov.number, NCTO1106352 .
10. Richardson P.G., Siegel D.S., Vij R. et al. Pomalidomide alone or in combination with lowdose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood. 2014; 123: 18–26.
11. DeFronzo R.A., Burant C.F., Fleck P. et al. Efficacy and tol erability of the DPP4 inhibitor alogliptin combined with pioglitazone, in metformintreated patients with type 2 dia betes. J. Clin. Endocrinol. Metab. 2012; 97 (5): 1615–1622.
12. Nauck M.A., Ellis G.C., Fleck P.R. et al. Efficacy and safety of adding the dipeptidyl peptidase4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inade quately controlled with metformin monotherapy: a multi centre randomised, duobleblind, placebocontrolled study. J. Clin. Pract. 2009; 63 (1): 46–55.
13. DeFronzo R.A., Fleck P., Wilson C. et al. Efficacy and safety of the dipeptidyl peptidase4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control. Diabet. Care. 2008; 31 (12): 2315–2317.
14. Lavalle'Gonzalez F.J., Januszewicz A., Davidson J. et al. Efficacy ahd safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on back ground metformin monotherapy: a randomised trial. Diabetologia. 2013; 56 (12): 2582–2592.
15. Gane E.J., Stedman C.A., Hyland R.H. et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N. Engl. J. Med. 2014; 368: 34–44.
16. Walmsley S.L., Antela A., Clumeck N. et al. Dolutegravir plus abacavirlamivudine for the treatment of HIV1 infection. N. Engl. J. Med. 2013; 369 (19): 1807–1818.
17. Donohue J.F., Maleki'Yazdi M.R., Kilbride S. et al. Efficacy and safety of oncedaily umeclidinium / vilanterol 42,5 /25 mcg in COPD. Respir. Med. 2013; 107 (10): 1538–1546.
18. Kerwin E.M., Scott'Wilson C., Sanford L. et al. A random ized trial of fluticasone / furoate / vilanterol (50 / 25 mcg; 100 / 25 mcg) on lung function in COPD. Respir. Med. 2013; 107: 560–569.
19. Pulido T., Adzerkho I., Channick R.N. et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N. Engl. J. Med. 2013; 369: 809–818.
20. Ghofrani H.'A., D'Armini A.M., Grimminger F. et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N. Engl. J. Med. 2013, 369, 319–329.
21. Elger C., Halasz P., Maia J. et al. Efficacy and safety of esli carbazepine acetate as adjunctive treatment in adults with refractory partial – onset seizures. A randomized, double blind, placebocontrolled, parallelgroup phase III study. Epilepsia. 2009; 50 (3): 453–464.
22. Fox R.J., Miller D.H., Phillips T. et al. Placebocontrolled phase 3 study of oral BG12 or glatiramer in multiple scle rosis. N. Engl. J. Med. 2012; 367 (12): 1087–1097.
23. Gold R., Kappos L., Arnold D.L. et al. Placebocontrolled phase 3 study of oral BG12 for relapsing multiple sclerosis. N. Engl. J. Med. 2012; 367 (12): 1098–1107.
Review
For citations:
Chuchalin A.G. Personalized genotyping!based therapy. PULMONOLOGIYA. 2014;(4):5-12. (In Russ.) https://doi.org/10.18093/0869-0189-2014-0-4-5-12
Views:
1271
Email this article 